A 70-year-old man with a history of heart failure with reduced EF and CKD stage 3 has type 2 diabetes with A1c 7.3% on metformin alone. He is already ...

Question

A 70-year-old man with a history of heart failure with reduced EF and CKD stage 3 has type 2 diabetes with A1c 7.3% on metformin alone. He is already on ACE inhibitor and beta-blocker. According to Canadian cardiovascular-diabetes guidance, which antihyperglycaemic agent would provide the greatest additional cardiovascular and renal benefit?

Accepted Answer

SGLT2 inhibitor (e.g., empagliflozin)

Answer

Dipeptidyl peptidase-4 inhibitor (e.g., sitagliptin)

Answer

Sulfonylurea (e.g., gliclazide)

Answer

Thiazolidinedione (e.g., pioglitazone)

Answer

Basal insulin

ca-mccqe1 MCQ (SBA): Cardiorenal risk reduction in type 2 diabetes